The Role of Autonomic Neuropathy in Predicting Ovarian Hyperstimulation Syndrome

Zahid Mohammed A. Kadhim
Department of Physiology and Medical Physics, College of Medicine, University of Babylon, Hillah, Iraq

Abstract

Background: Ovarian hyperstimulation syndrome (OHSS) is a life-threatening iatrogenic complication of ovarian stimulation during the assisted reproductive technique. Objective: This study was aimed to elucidate the effect of autonomic neuropathy on the occurrence of OHSS during assisted reproductive techniques. Materials and Methods: One hundred subfertile women underwent ovarian stimulation. The ovarian response was diagnosed by hormone concentrations and vaginal ultrasound. Autonomic function tests were done for all patients using Ewing’s protocol. Results: Twenty-eight percent of subfertile women involved in this study had autonomic neuropathy. Out of 100 infertile women undergoing ovarian stimulation, only 5 (5%) had been developed OHSS, all of them had autonomic neuropathy ($P < 0.05$). The sensitivity and specificity of the autonomic neuropathy for the occurrence of OHSS was 100% and 58% which was insignificant ($P > 0.05$). The best cutoff score associated with OHSS was ≥1.5 which detected from receiver operating characteristic curve. The odds ratio for the absence of OHSS in patients without neuropathy was 9.891, which was significant as compared with the patients with neuropathy ($P < 0.05$). Conclusion: The study concludes that ovarian stimulation may cause autonomic function disturbance which can predict OHSS.

Keywords: Autonomic function tests, ovarian hyperstimulation syndrome, subfertile women

INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovarian stimulation (mainly by gonadotropin therapy) used during assisted reproduction techniques. Approximately, 3%–6% of females undergoing ovarian stimulation may develop OHSS most of them have mild-to-moderately severe disease.$^{[1]}$ It is reported that the incidence of severe OHSS after gonadotropin stimulation is 0.1%–2%.$^{[2]}$

The disease is characterized by variable manifestations which typically begin within the first 24 h after the administration of human chorionic gonadotropin (hCG) and then became more severe within the next 7–10 days. These manifestations include hemoconcentration, pleural hemorrhage, ascites, and oliguria.$^{[3]}$

Many risk factors are seen to increase the incidence of developing OHSS including younger age, the presence of polycystic ovary syndrome, an exaggerated response to gonadotropin stimulation, and the development of multiple follicles (>20) before induction of ovulation.$^{[4]}$

The autonomic nervous system can affect several body functions; thus, autonomic dysfunction may present with different clinical features and neurophysiologic changes.$^{[5]}$ The autonomic nervous system has an important role in the control of the functions of the ovary.$^{[6]}$

Burden et al. demonstrated that the hilar perivascular plexus is a site where adrenergic nerves enter the ovary, then small branches from this plexus pass to the adjacent steroid-dependent interstitial gland cells.$^{[7]}$

Recently, Zangeneh et al. demonstrated that sympathetic efferent fibers have an important role in regulating the blood flow of ovaries (vasoconstrictor activity) and also causing inhibitory activity on ovarian estradiol secretion.$^{[8]}$ Furthermore, these efferent sympathetic fibers are activated by noxious cutaneous stimulation.$^{[6]}$

Address for correspondence: Dr. Zahid Mohammed A. Kadhim, Department of Physiology and Medical Physics, College of Medicine, University of Babylon, Hillah, Iraq. E-mail: zahidkadhim@gmail.com

How to cite this article: Kadhim ZA. The role of autonomic neuropathy in predicting ovarian hyperstimulation syndrome. Med J Babylon 2018;15:21-4.
Since OHSS is potentially fatal complication, so identification of patients at risk of it is important, so that they will not be treated with high-FSH doses and long GnRH-agonist protocols. At the same time, looking for factors that predict OHSS early can help in the prevention of the disease.

The study objectives are to investigate the role of autonomic neuropathy in patients planned to have ovarian stimulation in predicting OHSS.

**MATERIALS AND METHODS**

The present investigation was designed as a cohort study. Written informed consent was obtained from each participant. A total of 100 subfertile patients were included with age group from 19 to 43 years. The study is done at the period between February 2015 and July 2017. All patients undergo autonomic function tests at late follicular phase. All patients were downregulated according to the short protocol. Ovarian stimulation was performed with recombinant FSH or human menopausal gonadotropin.

The testing of autonomic functions was carried out in the morning, at a quiet room, and at the end of the follicular phase. Patients were advised to cease coffee consumption and eating for the last 2 h before the testing.

Cardiac autonomic neuropathy (CAN) was evaluated according to the Ewing’s protocol which uses five standard cardiovascular reflexes. It comprises Valsalva maneuver, response to deep breathing, orthostatic testing, and isometric exercise.

The severity of CAN was determined by gathering the results of the cardiovascular reflex testing [Table 1]. The results of each testing were marked as 0, 0.5, or 1 if it yielded normal, borderline, or abnormal estimate, respectively. Accordingly, the lowest and highest autonomic neuropathy results were 0 and 5, respectively. Consequently, autonomic neuropathy (AN) was defined as the presence of at least two abnormal tests or an AN results of ≥2.

Statistical analysis using mean with standard deviation of the variables between patients and control with receiver operating characteristic (ROC) curve for finding of cutoff value and sensitivity and specificity of the test was done also depending on Statistical Package for the Social Sciences (SPSS) software version 17, (IBM).

**RESULTS**

Twenty-eight percent subfertile women involved in this study had autonomic neuropathy.

**Cardiac autonomic neuropathy and intracytoplasmic sperm injection complication (ovarian hyperstimulation syndrome)**

Out of 100 infertile women undergoing intracytoplasmic sperm injection (ICSI), only 5 (5%) had been developed OHSS, all of them had autonomic neuropathy ($P < 0.05$), as shown in Figure 1.

Regarding OHSS and infertility causes, most of OHSS occur in female infertility group ($n = 4$) Figure 2.

The sensitivity and specificity of the CAN for the occurrence of complication (OHSS) was 100% and 58% which was insignificant ($P > 0.05$). The best cutoff score associated with OHSS was ≥1.5 which detected from ROC curve as shown in Figure 3 and Table 2.

![Figure 1: Autonomic neuropathy and the occurrence of ovarian hyperstimulation syndrome. CAN: Cardiac autonomic neuropathy, OHSS: Ovarian hyperstimulation syndrome](image1)

![Figure 2: OHSS and subfertility causes. CAN: Cardiac autonomic neuropathy, OHSS: Ovarian hyperstimulation syndrome](image2)

![Figure 3: Receiver operating characteristic curve for OHSS and CAN score. CAN: Cardiac autonomic neuropathy, OHSS: Ovarian hyperstimulation syndrome](image3)
In binary logistic regression analysis, CAN shows statistically significant relationship with the existence of OHSS. The odds ratio (OR) for the presence of OHSS in patients with neuropathy was 5.625 (95% confidence interval (CI) 0.004–7066.341), as compared with the patients with no neuropathy [Table 3], and the OR for the absence of OHSS in patients without neuropathy was 9.891 (95% CI 1.038–94.229), which was significant as compared with the patients with neuropathy ($P < 0.05$).

**DISCUSSION**

It is well-known OHSS is a life-threatening iatrogenic disease, and so its prediction is a vital step in its prevention and treatment.

To the best of our knowledge, this is the first study analyzing the effect of preexisting autonomic neuropathy on the prediction of OHSS, and we found that at 1.5 neuropathy score the sensitivity for predicting OHSS was 100% and specificity 58%.

Accordingly, we recommend screening for women planned to have artificial ovarian induction, especially those at high risk for autonomic neuropathy like those with diabetes mellitus, repeated cycle of ovarian stimulation, smokers, or on drugs that impair the autonomic function (like $\alpha$ and $\beta$ agonist or antagonist).

**Table 1: Autonomic neuropathy score according to Ewing’s protocol**

| AN score | Sum of points | AN            |
|----------|---------------|---------------|
| 0        | 0             | Absent        |
| 1        | 0.50–1.5      | Early         |
| 2        | 2–3           | Definite      |
| 3        | $\geq$3.5     | Severe        |

AN: Autonomic neuropathy

**Table 2: Sensitivity and specificity of autonomic neuropathy for the occurrence of ovarian hyperstimulation syndrome**

| Area | Cutoff point | Sensitivity (%) | Specificity (%) | $P$ | 95% CI Lower bound | 95% CI Upper bound |
|------|--------------|----------------|----------------|-----|--------------------|--------------------|
|      |              |                |                |     |                    |                    |
| 0.604| 1.5          | 100            | 58             | 0.124 | 0.589             | 0.826              |

CI: Confidence interval

**Table 3: Binary logistic regression analysis for ovarian hyperstimulation syndrome as the dependent variable**

| CAN | OHSS | $P$ | OR | 95% CI for odds ratio |
|-----|------|-----|----|-----------------------|
| With| With | 0.635 | 5.625 | 0.004 | 7066.341 |
| Without| Without | 0.046* | 9.891 | 1.038 | 94.229 |

*Significant. CI: Confidence interval, OR: Odds ratio, OHSS: Ovarian hyperstimulation syndrome, CAN: Cardiac autonomic neuropathy

The explanation for this finding is that since the exact pathophysiological mechanism of OHSS is not yet discovered and the most acceptable one is that OHSS results from increased vascular permeability in the region surrounding the ovaries. On the other hand, the autonomic nervous system has a profound role in maintaining the vascular integrity and homeostasis. Consequently, any impairment of autonomic nervous system is thought to have added detrimental effect on the vascular system and thus on developing OHSS.

Several researchers$^{[6-8]}$ studied the effect of the autonomic nervous system on ovarian function, but this function is not yet fully clarified. As well as, no previous study investigated the role of autonomic neuropathy in predicting of OHSS during ovarian stimulation.

Many researchers found that OHSS is accompanied by elevation in the level of estradiol 2 and so they assume that estradiol 2 essay is an important marker to detect the majority of patients at risk of OHSS.$^{[11]}$ On the same assumption, some investigators said that monitoring $E_2$ was found to be effective in reducing the incidence of OHSS.$^{[12]}$ However, a level of $E_2$ threshold of 3000 pg/mL will predict only one-third of the total OHSS cases, while applying the best threshold value of 2560 pg/mL, less than half of the severe cases will be predicted (49% sensitivity and 77% specificity).$^{[11]}$

While Elprince et al.$^{[4]}$ found that vascular endothelial growth factor and tissue factor can predict OHSS.$^{[4]}$

On the other hand, Griesinger demonstrated that the optimal threshold of follicles $\geq$11-mm identify those at risk of OHSS was 19 follicles (sensitivity and specificity, 62.3% and 75.6%, respectively). The positive and negative predictive values were 6.9% and 98.6%, respectively.$^{[13]}$

In the present study, autonomic neuropathy scores were estimated according to Ewing’s protocol.$^{[12]}$ Based on the above facts, it is advised to monitor the level of estradiol $E_2$ and number of follicles on the day of hCG administration and delaying or cancelling it until the level of estradiol return to safe value (coasting protocol)$^{[12]}$.

Zhao et al.$^{[9]}$ demonstrated that microRNA (are a class of small noncoding RNAs that function as translational repressors) can be considered as biomarkers found in the blood for predicting OHSS in patients with polycystic ovarian syndrome.$^{[14]}$

The causes of autonomic neuropathy may be due to diabetes mellitus, nutritional factors (Vitamin B12 deficiency), hormonal factor, drugs used in controlled ovarian hyperstimulation, stress, genetic, or due to environmental factors.$^{[15]}$

Multiple therapeutic approaches are employed for the prevention of OHSS, including cycle cancellation, decreasing the dose gonadotropin (Gn),$^{[20]}$ decreasing HCG dose or even induction of ovulation with GnRH – a trigger.$^{[16,17]}$ Cancellation of fresh embryo transfer, and also administration of hydroxyethyl starch or acetylsalicylic acid to prohibit aggravation of OHSS. Nonetheless, none of these approaches can eradicate the occurrence and progression of OHSS.$^{[18]}$
In vitro fertilization/ICSI stimulation protocol using HCG or LH usually induces maturation of multiple follicles in each ovary. This results in the release of vasoactive substances which act to increase vascular permeability, accumulation of fluid in third space, increase concentration of blood, and hypovolemia. All these events will induce OHSS.\[19\]

**Conclusion**

Autonomic neuropathy is an important predictive factor of OHSS and should be kept in mind as risk factor for the disease.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Corbett S, Shmorgun D, Claman P, reproductive endocrinology infertility committee, special contributor. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 2014;36:1024-33.
2. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-96.
3. D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011;15:CD002811.
4. Elprince M, Wang F, Zhu Y, Huang H. Prediction of ovarian hyperstimulation syndrome (OHSS) and the effect of low molecular weight (LMWH) on its pathogenesis in controlled ovarian hyperstimulation: Does it have a role in its prevention? Fertil Steril 2011;96 Suppl 3:S260.
5. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387-97.
6. Uchida S, Kagitani F. Effects of electrical stimulation of autonomic nerves to the ovary on the ovarian testosterone secretion rate in rats. Auton Neurosci 2014;180:48-52.
7. Borden HW, Leonard M, Smith CP, Lawrence IE Jr. The sensory innervation of the ovary: A horseradish peroxidase study in the rat.
8. Zangeneh F, Naghizadeh M, Minaei B, Aminee F. PCOS and sympathetic outcome: Role of the central and peripheral nervous system in ovarian function of rat. Asian J Pharm Clin Res 2012;5:26-32.
9. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function test: 10 years' experience in diabetes. Diabetes Care 1985;8:491-8.
10. O’Brien IA, O’Hare JP, Lewin IG, Corrall RJ. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: A controlled study based on heart rate variability. Q J Med 1986;61:957-67.
11. Aboghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod 2003;18:1140-1.
12. Aljawoan FY, Hunt LP, Gordon UD. Prediction of ovarian hyperstimulation syndrome in coated patients in an IVF/ICSI program. J Hum Reprod Sci 2012;5:32-6.
13. Griesinger G. OHSS: Prediction, Prevention and Treatment Can we Reliably Predict OHSS ?; 2008.
14. Zhao C, Liu X, Shi Z, Zhang J, Zhang J, Jia X, et al. Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. Cell Physiol Biochem 2015;35:1086-94.
15. Vinik A, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol 2013;117:279-94.
16. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: A prospective randomised controlled trial (RCT). Hum Reprod 2010;25:683-9.
17. Stadmayer LA, Sarhan A, Duran EH, Beydoun H, Bocca S, Pultz B, et al. The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: A prospective randomized study. Fertil Steril 2011;95:216-20.
18. Chen C, Liu L, Geng Y, Yang C, Li T, Gao Y. Prevention and treatment of OHSS by administration of GnRH antagonist in the early luteal phase of controlled ovarian hyperstimulationcycles. Int J Clin Exp Pathol 2017;10:2193-8.
19. Chen SU, Chou CH, Lin CW, Lee H, Wu JC, Lu HF, et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: Dopamine targets their common pathways. Hum Reprod 2010;25:757-67.